Cargando…
ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment
BACKGROUND: Measurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects of nifurtimox administered by two different...
Autores principales: | Rivero, Rocio, Esteva, Mónica Inés, Huang, Erya, Colmegna, Leylen, Altcheh, Jaime, Grossmann, Ulrike, Ruiz, Andrés Mariano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325040/ https://www.ncbi.nlm.nih.gov/pubmed/37352322 http://dx.doi.org/10.1371/journal.pntd.0011440 |
Ejemplares similares
-
Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina
por: Vizcaya, David, et al.
Publicado: (2021) -
Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)
por: Altcheh, Jaime, et al.
Publicado: (2023) -
Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
por: Altcheh, Jaime, et al.
Publicado: (2021) -
Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease
por: Stass, Heino, et al.
Publicado: (2020) -
Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)